Consideration of use of neuraminidase inhibitors such as oseltamivir and zanamivir in IgA nephropath

被引:1
作者
Altschuler, EL
Bhatia, A
Kast, RE
机构
[1] Univ Med & Dent New Jersey, Newark, NJ 07101 USA
[2] Univ Vermont, Burlington, VT 05401 USA
关键词
D O I
10.1111/j.1523-1755.2005.00583_7.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:2910 / 2911
页数:2
相关论文
共 4 条
[1]   Aberrant glycosylation in IgA nephropathy (IgAN) [J].
Coppo, R ;
Amore, A .
KIDNEY INTERNATIONAL, 2004, 65 (05) :1544-1547
[2]   Neuraminidase inhibitor, oseltamivir blocks GM1 ganglioside-regulated excitatory opioid receptor-mediated hyperalgesia, enhances opioid analgesia and attenuates tolerance in mice [J].
Crain, SM ;
Shen, KF .
BRAIN RESEARCH, 2004, 995 (02) :260-266
[3]   Influenza [J].
Nicholson, KG ;
Wood, JM ;
Zambon, M .
LANCET, 2003, 362 (9397) :1733-1745
[4]   Aberrantly glycosylated serum IgA1 are closely associated with pathologic phenotypes of IgA nephropathy [J].
Xu, LX ;
Zhao, MH .
KIDNEY INTERNATIONAL, 2005, 68 (01) :167-172